Company: PSTV
Filing Date: 2025-04-23
Form Type: S-3/A
Source: 0001193125-25-091456
Chunk: 34

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-23
Form: S-3/A
Chunk 34
---
     |             |            |
| 23.2**  |     | Consent of Hogan Lovells US LLP (included in Exhibit 5.1 hereto).                                          |     |                           |      |     |             |            |     |         |       |     |             |            |
| 24.1    |     | Power of Attorney.                                                                                         |     |                           | S-3  |     |             | 333-286393 |     |         |  24.1 |     |             | 04/04/2025 |
| 24.2*   |     | Power of Attorney.                                                                                         |     |                           |      |     |             |            |     |         |       |     |             |            |
| 107.1   |     | Filing Fee Table.                                                                                          |     |                           | S-3  |     |             | 333-286393 |     |         | 107.1 |     |             | 04/04/2025 |

| * | Filed herewith. |

| ** | To be filed by amendment. |

Item 17. Undertakings (a) The undersigned registrant hereby undertakes: (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

| (i) | to include any prospectus required by Section 10(a)(3) of the Securities Act; |

II-3

| (ii) | to reflect in the prospectus any facts or events arising after the effective date of the registration statement                                                                                                                                         
 (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in    
 volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus 
 filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Table” in the effective          
 registration statement; and                                                                                                                                                                                                                             |

| (iii) | to include any material information with respect to the plan of distribution not previously disclosed in the 
 registration statement or any